In this article, we will discuss Ivosidenib (Dosage Overview). So, let’s get started.
Indications
Acute Myeloid Leukemia
Ivosidenib is indicated for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible isocitrate dehydrogenase-1 (IDH1) mutation as detected by an FDA-approved test.
Dosage
Patient Selection
Select patients for the treatment of AML with Ivosidenib based on the presence of IDH1 mutations in the blood or bone marrow. Patients without IDH1 mutations at diagnosis should be retested at relapse because a mutation in IDH1 may emerge during treatment and at relapse.
Recommended Dosage
The recommended dose of Ivosidenib is 500 mg taken orally once daily until disease progression or unacceptable toxicity. For patients without disease progression or unacceptable toxicity, treat for a minimum of 6 months to allow time for clinical response.
(Administer Ivosidenib with or without food. Do not administer Ivosidenib with a high-fat meal because of an increase in ivosidenib concentration. Do not split or crush Ivosidenib tablets. Administer Ivosidenib tablets orally about the same time each day. If a dose of Ivosidenib is vomited, do not administer a replacement dose; wait until the next scheduled dose is due. If a dose of Ivosidenib is missed or not taken at the usual time, administer the dose as soon as possible and at least 12 hours prior to the next scheduled dose. Return to the normal schedule the following day. Do not administer 2 doses within 12 hours).